Phase II Study to Evaluate the Effects of Cabozantinib in Patients With Unresectable/Metastatic Adrenocortical Carcinoma
Phase of Trial: Phase II
Latest Information Update: 09 Oct 2019
Price : $35 *
At a glance
- Drugs Cabozantinib (Primary)
- Indications Adrenocortical carcinoma
- Focus Therapeutic Use
- Acronyms CaboACC
- 04 Jun 2019 Trial design for two phase II studies including this study presented at the 55th Annual Meeting of the American Society of Clinical Oncology
- 18 Mar 2019 Status changed from not yet recruiting to recruiting, according to design presented at the 101st Annual Meeting of the Endocrine Society.
- 18 Mar 2019 Rationale and protocol of NCT03370718 and NCT03612232 studies were presented at the 101st Annual Meeting of the Endocrine Society.